arrow
E

Elisabetta Munzone

irccs european institute of oncology
H指数:40
被引数:8,264

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study

激素受体阳性、HER2阴性乳腺癌患者中第二次同侧局部区域复发的队列研究

2026-08-010
PRE
Interplay Between HER2-Low Status, Hormone Receptor Expression, and Therapeutic Response to Cyclin-Dependent Kinase 4/6 Inhibitors as First-Line Treatment in Luminal-like Metastatic Breast Cancer: The CYCLHER Study

ER2低表达状态、激素受体表达与细胞周期蛋白依赖性激酶4/6抑制剂作为luminal样转移性乳腺癌一线治疗的疗效反应的相互作用:CYCLHER研究

2026-05-190
OAAI
Deciphering the Role of Cancer Stem Cells in Breast Cancer Brain Colonization Using a Novel Patient-Derived Model

利用一种新型患者来源模型,解析癌症干细胞在乳腺癌脑转移中的作用

2026-03-270
OAAI
Impact of Breast Cancer on Sexuality and Psycho-Physical Wellbeing: Survey Analysis

乳腺癌对性功能和身心健康的影晌:调查分析

2026-03-090
OAAI
Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study☆

乳腺癌手术和全身治疗在初诊转移性乳腺癌伴局部区域寡进展患者中的持续应用:一项队列研究☆

2025-12-100
OAAI
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study

针对伴有内脏寡进展或寡持续存在的转移性乳腺癌患者的转移灶导向热消融:一项队列研究

2025-11-260
OAAI
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study

转移性三阴性炎性乳腺癌患者的免疫检查点抑制剂 (integrle): 一项国际队列研究

2024-12-010
PRE
Development and Validation of a Natural Language Processing Algorithm for Extracting Clinical and Pathological Features of Breast Cancer From Pathology Reports
2024-08-010
PRE
Long-term outcome of invasive pure micropapillary breast cancer compared with invasive mixed micropapillary and invasive ductal breast cancer: a matched retrospective study
2024-07-040
PRE
Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis
2024-05-020
PRE
Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
2024-05-024
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
2024-03-011
PRE
Real-world use of multigene signatures in early breast cancer: differences to clinical trials

多基因签名在早期乳腺癌中的实际应用: 与临床试验的差异

2024-01-241
OAAI